Search Results - "Yel, D"

Biochemical validation of self reported quit rates among Buddhist monks in Cambodia by Yel, D, Hallen, G K, Sinclair, R G, Mom, K, Srey, C T

“…Table 1 Self reported quit rates of Cambodian Buddhist monks Smoking status Accurate self report False self report Total (n) Concordance (%) (n) % (n)…”
Get full text

Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery by Li, Zhongqiu, Van Bergen, Tine, Van de Veire, Sara, Van de Vel, Isabelle, Moreau, Huberte, Dewerchin, Mieke, Maudgal, Prabhat C, Zeyen, Thierry, Spileers, Werner, Moons, Lieve, Stalmans, Ingeborg

“…Filtration failure due to excessive postoperative scarring remains a major problem after glaucoma surgery. The authors have investigated whether glaucoma and…”
Get full text

Biochemical validation of self reported quit rates among Buddhist monks in Cambodia: Table 1 by Yel, D, Hallen, G K, Sinclair, R G, Mom, K, Srey, C T

Get full text

Improved Treatment Satisfaction with a New Human Subcutaneous Immunoglobulin (SCIG 20%) in Patients Previously Treated with IVIG by Meckley, Lisa, PhD, Ito, Diane, MA, Hu, Xingdi, PhD, Berner, Todd, MD, Yel, Leman, MD, FAAAAI

“…Patients also reported improvement relative to the IVIG therapy period after treatment with SCIG 20% in the Therapy Setting LQI domain, improving from 17.5 to…”
Get full text

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20 by Paris, Kenneth, MD, MPH, Haddad, Elie, MD, PhD, Hussain, Iftikhar, Brodszki, Nicholas, MD, PhD, Darter, Amy Liebl, MD, FAAAAI, Engl, Werner, PhD, McCoy, Barbara, PhD, Yel, Leman, MD, FAAAAI

“…Conclusions SCIG 20% treatment was safe and well tolerated at high infusion rates and volumes per site with short infusion durations, offering a favorable Ig…”
Get full text

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America by Suez, Daniel, MD, FAAAAI, Krivan, Gregely, PhD, Jolles, Stephen R., MD, Hussain, Iftikhar, Stein, Mark R., MD, FAAAAI, Gupta, Sudhir, MD, Ph.D, MACP, Paris, Kenneth, MD, MPH, van Hagen, Martin, Brodszki, Nicholas, MD, PhD, McCoy, Barbara, PhD, Yel, Leman, MD FAAAAI

“…Rationale Cuvitru, a new human immune globulin (Ig) subcutaneous, 20% (SCIG 20%) ready-for-use, liquid preparation of highly purified human IgG, was well…”
Get full text

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs) by Gupta, Sudhir, MD, PhD, MACP, Stein, Mark R., MD, FAAAAI, Melamed, Isaac Reuven, MD, Hussain, Iftikhar, Paris, Kenneth, MD, MPH, Engl, Werner, PhD, McCoy, Barbara, PhD, Rabbat, Christopher J., PhD, Yel, Leman, MD, FAAAAI

“…Rationale Data from a phase 2/3 North American clinical trial provided an opportunity to understand the onboarding experience of a new SCIG 20% in patients…”
Get full text

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies by Wasserman, Richard L., MD, PhD, FAAAAI, Gupta, Sudhir, MD, PhD, MACP, Stein, Mark R., MD, FAAAAI, Melamed, Isaac Reuven, MD, Puck, Jennifer M., MD, Engl, Werner, PhD, Leibl, Heinz, PhD, Rabbat, Christopher J., PhD, Yel, Leman, MD, FAAAAI

“…Conclusions Long-term evaluation of the same patient cohort over three consecutive studies demonstrated that IGHy, compared to the other modes of Ig therapy…”
Get full text

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America by Suez, Daniel, MD, FAAAAI, Melamed, Isaac, MD, Hussain, Iftikhar, MD, FAAAAI, Stein, Mark R., MD, FAAAAI, Gupta, Sudhir, MD, PhD, FAAAAI, Paris, Kenneth, MD, MPH, Fritsch, Sandor, PhD, Bourgeois, Christelle, PhD, Leibl, Heinz, PhD, McCoy, Barbara, PhD, Yel, Leman, MD, FAAAAI

“…Results Seventy-four patients aged 3-83 years received IGSC 20% and 67 completed; no patient discontinued IGSC 20% due to a serious adverse event (SAE) or…”
Get full text

Bedside sonographic measurement of optic nerve sheath diameter as a predictor of intracranial pressure in Emergency Department by Komut, Erdal, MD, Kozacı, Nalan, Sönmez, Bedriye Müge, MD, Yılmaz, Fevzi, MD, Komut, Seval, MD, Yıldırım, Zeliha Nilgün, MD, Beydilli, İnan, MD, Yel, Cihat, MD

“…Abstract Background Ocular ultrasonography (USG) of optic nerve sheath diameter (ONSD) to determine intracranial pressure (ICP) has become favorable in recent…”
Get full text

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies by Stein, Mark R., MD, FAAAAI, Wasserman, Richard L., MD, PhD, FAAAAI, Melamed, Isaac, MD, Gupta, Sudhir, MD, PhD, FAAAAI, Kobrynski, Lisa J., MD, MPH, FAAAAI, Rubinstein, Arye, MD, FAAAAI, Rabbat, Christopher J., PhD, Engl, Werner, PhD, McCoy, Barbara, PhD, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI

“…Rationale IGHy can be administered at similar doses/volumes and dosing intervals as intravenous immunglobulin G (IgG) (IGIV) but, similar to conventional…”
Get full text

Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time by Wasserman, Richard L., MD, PhD, FAAAAI, Stein, Mark R., MD, FAAAAI, Kobrynski, Lisa J., MD, MPH, FAAAAI, Gupta, Sudhir, MD, PhD, FAAAAI, Grant, J. Andrew, MD, FAAAAI, Rubinstein, Arye, MD, FAAAAI, Rabbat, Christopher J., PhD, Engl, Werner, PhD, McCoy, Barbara, PhD, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI

“…Over the course of IGHy treatment, serum trough levels of antibodies to Haemophilus influenza, Clostridium tetani toxoid, and hepatitis B virus were protective…”
Get full text

Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI) by Wasserman, Richard L., MD, PhD, FAAAAI, Stein, Mark R., MD, FAAAAI, Melamed, Isaac, MD, Kobrynski, Lisa J., MD, MPH, FAAAAI, Gupta, Sudhir, MD, Puck, Jennifer M., MD, Rubinstein, Arye, MD, Engl, Werner, McCoy, Barbara, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI

“…Conclusions IGHy administered at a frequency similar to IGIV over 3 years was effective in maintaining low infection rates in patients with PI, and the AE…”
Get full text

Exposure to Environmental Tobacco Smoke in the Nonsmoking Population of Cambodia by Rudatsikira, Emmanuel M., MD, MPH, Knutsen, Synnove F., MD, PhD, Job, Jayakaran S., MD, DrPH, Singh, Pramil N., DrPH, Yel, Daravuth, MD, MS, Montgomery, Susanne B., PhD, MPH, Petersen, Floyd F., MPH, Ferry, Linda H., MD, MPH

“…Objective To estimate the extent of environmental tobacco smoke (ETS) exposure among nonsmokers in the adult population of Cambodia. Methods A cross-sectional…”
Get full text

Safety and Tolerability of an Intravenously-administered Alpha1-Proteinase Inhibitor (A1PI) at an Increased Infusion Rate: A Randomized, Placebo-Controlled, Phase 4 Study in Healthy Adults by Haeberle, Adam, PhD, Ngo, Leock, PhD, Inhaber, Niel, MD, Gelmont, David, MD, Yel, Leman, MD

Get full text